Embolization with transient materials

Patent metadata

Field	Value
Publication number	US-2024189491-A1
Application number	US-202418584895-A
Country	US
Kind code	A1
Filing date	Feb 22, 2024
Priority date	May 10, 2019
Publication date	Jun 13, 2024
Grant date	—

Abstract

Use of embolic material that is biodegradable provides for embolizing a hypervascular vessel formed in response to chronic inflammation in a musculoskeletal vasculature or a vessel related to production of ghrelin. The embolic material is biodegradable within a predetermined period of time. Medical systems are configured for delivery of embolic material for embolizing the hypervascular vessel or the vessel related to production of ghrelin.

First claim

What is claimed is:

1 . A method of embolizing a hypervascular vessel formed in response to chronic inflammation in a musculoskeletal vasculature, the method comprising:
advancing a catheter through a vasculature to a parent artery; and releasing an embolic material from a distal end of the catheter into the hypervascular vessel, with the embolic material blocking blood flow in the hypervascular vessel without blocking blood flow to a parent vessel, wherein the embolic material is free of a therapeutic agent and comprises deformable hydrogel particles that are biodegradable within a period of time from 15 minutes to 48 hours.

2 . The method of claim 1 wherein the particles have an average diameter from about 20 microns to about 300 microns.

3 . The method of claim 1 wherein the particles have an average diameter from about 20 microns to about 250 microns.

4 . The method of claim 1 wherein the particles are substantially spherical.

5 . The method of claim 1 wherein the particles are of polymeric origin.

6 . The method of claim 1 wherein the particles comprise gelatin.

7 . The method of claim 1 wherein the particles comprise crosslinked gelatin.

8 . The method of claim 1 wherein the particles are hydrolytically degradable.

9 . The method of claim 1 wherein the particles are biodegradable by enzymatic action.

10 . The method of claim 1 wherein the particles are biodegradable by collagenase.

11 . The method of claim 1 wherein the particles are biodegradable to biocompatible residues.

12 . The method of claim 1 wherein the embolic material further comprises a contrast agent.

13 . The method of claim 1 wherein the period of time is from 15 minutes to 8 hours.

14 . The method of claim 1 being a treatment for an area related to a heel, spine, shoulder, hip, knee, or elbow.

15 . A medical system for treatment of a hypervascular vessel formed in response to chronic inflammation in a musculoskeletal vasculature, the medical system comprising:
a catheter suitable for delivery through a patient's vasculature to reach the hypervascular vessel; and a delivery component comprising a reservoir of the embolic material configured for delivery through the catheter, wherein the embolic material is free of a therapeutic agent and comprises deformable hydrogel particles that are biodegradable within a period of time from 15 minutes to 48 hours.

16 . The medical system of claim 15 wherein the delivery component comprises a syringe or pump.

17 . The medical system of claim 15 wherein the catheter comprises a 1.7F to 3F catheter.

18 . The medical system of claim 15 wherein the particles comprise gelatin.

19 . The medical system of claim 15 wherein the particles are hydrolytically degradable.

20 . The medical system of claim 15 wherein the particles are biodegradable by enzymatic action.

Assignees

• Incept Llc

Inventors

• Sawhney Amarpreet S
• Jarrett Timothy S
• Claesson Hans

Classifications

• A61M2202/0413

  Blood · CPC title

• A61M2025/091

  having a lumen for drug delivery or suction · CPC title

• A61M2202/0466

  Saliva · CPC title

• A61M2210/1003

  Spinal column · CPC title

• A61M2210/083

  Arms · CPC title